# Vandetanib in Advanced NSCLC With RET Rearrangement

> **NCT01823068** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 17 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Vandetanib

## Key facts

- **NCT ID:** NCT01823068
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-03
- **Primary completion:** 2014-12-29
- **Final completion:** 2018-03-16
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01823068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01823068, "Vandetanib in Advanced NSCLC With RET Rearrangement". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01823068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*